Tegaserod-associated ischemic colitis

Pharmacotherapy

Volumn 25, Issue 4, 2005, Pages 620-625

  DiBaise, John K ^a  

^a MAYO CLINIC   (United States)

Author keywords

IBS; Irritable bowel syndrome; Ischemic colitis; Tegaserod

Indexed keywords

ALPRAZOLAM; AZATHIOPRINE; CITALOPRAM; CLONAZEPAM; CORTICOSTEROID; DOCUSATE SODIUM; INFLIXIMAB; LANSOPRAZOLE; MACROGOL; MAGNESIUM HYDROXIDE; MESALAZINE; OMEPRAZOLE; ONDANSETRON; PROMETHAZINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEROTONIN 4 RECEPTOR; TEGASEROD;

ABDOMINAL PAIN; CONSTIPATION; CROHN DISEASE; DIARRHEA; DRUG LABELING; HEMATOCHEZIA; HUMAN; IRRITABLE COLON; ISCHEMIC COLITIS; PRESCRIPTION; REVIEW;

ADULT; COLITIS, ISCHEMIC; FEMALE; HUMANS; INDOLES; IRRITABLE BOWEL SYNDROME; RECEPTORS, SEROTONIN, 5-HT4; SEROTONIN AGONISTS;

EID: 16344363012     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.25.4.620.61032     Document Type: Review

References (35)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
2. Drossman DA, Thompson WG. The irritable bowel syndrome: review and a graduated multicomponent treatment approach. Ann Intern Med 1992;116:1009-16.
3. Akehurst R, Kaltenhaler E. Treatment of irritable bowel syndrome: a review of randomized controlled trials. Gut 2001;48:2272-82.
4. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002;97:S7-26.
5. 4 partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:1745-51.
6. 4 receptor partial agonist, decreased sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003;17:577-85.
7. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463-8.
8. Jensen DM, Zarimani AI, Dovacs TOG, et al. Ischemic colitis is a common cause of severe hematochezia and patient outcomes are no worse than with other colonic diagnoses [abstr]. Gastrointest Endosc 2004;59:AB105.
9. Forde KA, Lebwohl O, Wolff M, Vorhees AB. The endoscopy corner: reversible ischemic colitis-correlation of colonoscopic and pathologic changes. Am J Gastroenterol 1979;72:182-5.
10. Dignan CR, Greenson JK. Can ischemic colitis be differentiated from C difficile colitis in biopsy specimens? Am J Surg Pathol 1997;21:706-10.
11. Fry LC, Singh S, Moenkemueller KE. Left-sided ischemic colitis revisited: a prospective endoscopic, pathologic, radiologic and clinical study [abstr]. Gastrointest Endosc 2004;59:AB104.
12. Habu Y, Tahashi Y, Kiyota K, et al. Reevaluation of clinical features of ischemic colitis-analysis of 68 consecutive cases diagnosed by early colonoscopy. Scand J Gastroenterol 1996;31:881-6.
13. Matsumoto T, Iida M, Kimura Y, Nanbu T, Fujishima M. Clinical features in young adult patients with ischemic colitis. J Gastroenterol Hepatol 1994;9:572-5.
14. Cole JA, Cook SF, Sands BE, et al. Occurrence of colon ischemia in relation to irritable bowel syndrome. Am J Gastroenterol 2004;99:486-91.
15. Walker AM, Bohn RL, Cali C, Cook S, Ajene AN, Sands BE. Risk factors for colonic ischemia. Am J Gastroenterol 2004;99:1333-7.
16. Cappell MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-90.
17. Tougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002;16:1701-8.
18. Freidel D, Thomas R, Fisher RS. Ischemic colitis during treatment with alosetron. Gastroenterology 2001;120:557-60.
19. GlaxoSmithKline. Lotronex (alosetron hydrochloride) tablets: Briefing document for the joint gastrointestinal drugs advisory committee and drug safety and risk management committee. Available from http://www.fda.gov/ohrms/dockets/ ac/02/ briefing/3848B1_02_FDA%20Lotronex.pdf. Accessed February 4, 2005.
20. Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. Am J Gastroenterol 2003;98:1117-22.
21. Higgins PDR, Davis KJ, Laine L. Systematic review: the epidemiology of ischaemic colitis. Aliment Pharmacol Ther 2004;19:729-38.
22. Loftus EV, Sandborn WJ, Tremaine WJ, et al. Incidence of ischemic colitis in Olmsted County, Minnesota, 1976-1998 [abstr]. Am J Gastroenterol 2002;97:S121-2.
23. Singh G, Mithal A, Triadafilopoulos G. Patients with irritable bowel syndrome have a high-risk of developing ischemic colitis [abstr]. Gastroenterology 2004;126:A41.
24. Beck IT. Possible mechanisms for ischemic colitis during alosetron therapy. Gastroenterology 2001;121:231-2.
25. Novartis Pharmaceuticals. Data on file. East Hanover, NJ; 2004.
26. Wood AJ, Stein CM, Woosley R. Making medicines safer: the need for an independent drug safety board. N Engl J Med 1998;339:1851-4.
27. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med 2004;140:795-801.
28. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000;356:1255-9.
29. Gershon MD. Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999;13:15-30.
30. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004;126:1657-64.
31. Knudsen JF, Friedman B, Chen M, Goldwasser JE. Ischemic colitis and sumatriptan use. Arch Intern Med 1998;158:1946-8.
32. Bradette M, Moennikes H, Carter F, et al. Cilansetron in irritable bowel syndrome with diarrhea predominance (IBS-D): efficacy and safety in a 6 month global study [abstr]. Gastroenterology 2004;126:A42.
33. Novartis Pharmaceuticals. Zelnorm (tegaserod maleate) package insert. East Hanover, NJ; 2004.
34. 3 receptor antagonists, alosetron and cilansetron, impair mesenteric blood flow in rats [abstr]. Gastroenterology 2003;124:A148-9.
35. Lopez JA, Brown BP, Armstrong ML, Piegors DJ, Heistad DD. Response of the mesenteric circulation to serotonin in normal and atherosclerotic monkeys: implications for the pathogenesis of non-occlusive intestinal ischemia. Cardiovasc Res 1989;23:117-24.